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I.

The Problem

Neural tube defects (NTD) is a collective term for a group of birth
defects which include anencephaly, encephalocele and spina bifida. In
California, the incidence of NTD is I. I per thousand live births. By type
and incidence, NTD can be subgrouped as: 1
Anencephaly
Encephalocele
Spina bifida

0.5 / 1000
0.08/1000
0.5 / 1000

Anencephaly is incompatible with life- the affected neonate succumbs
within a few hours of birth. Encephalocele is rare and generally results in
some degree of mental disability.
Spina bifida will affect approximately 185 newborn infants in California
each year. Successful treatment exists for most cases of even the worst
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physical disability, and most of these children are not mentally impaired.
NTD, therefore, is not a leading cause of morbidit y and mortalit y for
children in California; rather, it is a potenti a ll y handicapping di sorder for
which effective postnatal therapy has generally been reali 7.ed .
The technology now exists which enables the d etection of only eight y
percent of neural tube defects during the middle of pregnancy. This
technology consists of screening the se rum of their mothers for alphafetoprotein during the 16th to th e 18th week of pregnancy. Alphafetoprotein is the fetal analogue of ad ult albumin, and it is usuall y e levated
in both the maternal se rum and the amniotic fluid if the developing human
is affected with an NTD or o mphalocele. Inte resting ly, th e maternal se rum
alpha-fetoprotein (MSAFP) is depressed in some insta nces when th e
developing human has Down's syndrome.
II.

Informative Digest

In 1982, Section 289.7 of the Health and Safety Code was amended.
requiring the Department of Health Services to promulga te regulations
governing th e alpha-fetoprotein test kits that were soon to be approved for
marketing by the FDA. The intent of the legislative mandate was to
protect the public from un sc rupulous marke ting by the private sector
which could lead to inaccurate testing and misinterpretation of test
results 2 The department fail ed to provide re g ulations . and the leg islature
therefore amended the FY 1983 / 84 Budget Act requiring emergency
regulations . It was never the int ent of the legislature to implement a
mandatory statewide alpha-fetoprotein screening program . and this fact is
appropriately demonstrated by th e rejecti o n of the emergency legislation
AB 1846 (Margolin) in 1985 .
Lori Andrews, J.D .. project director in medical law for the American
Bar Foundation, qu estions whether such re g ulations can be responsive to
public opinion: "If you're going to make policies that force peo ple to
undergo medical services. should th e decisions be made i ~ a back room or
in the legislature where all inte res ts are heard 'l"l Nevertheless. the
regulations were drafted in a "back room" fashion and subsequently
implemented. contrary to leg islati ve intent.
III.

The Position of Professional Organizations

In 19 82, respo ndin g to the call to screen all preg na nt women for NTDs,
the American College of Obstetrics and Gynecology (ACOG) stated: "The
risks an d costs appear to outweigh the advantages and the prog ram should
not be implemented ."4
Contrary to the misinformation which has been promulgated . the
ACOG has never altered it s position. The American Medical Association
(AMA) stands by its report by th e Council on Scientific Affairs which
concluded: "Maternal serum alpha-fetoprotein screening of all pregnant
women should not be advocated at this time ."5
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The following discussion will clarify the reasons why the ACOG and the
A M A hold this position.
The Program
In California, 370,000 women annually are in prenatal care by the 16th
to the 18th week of pregnancy.6 Using available statistics 7, 8,9, the statewide
program in California will work as is shown in Tables I and II.
Neural Tube Defects
The problem with the NTD screening program is the lack of reliability of
the serum alpha-fetaprotein test. The test is falsely positive (that is ,
unaffected women will test as if their baby is affected) in 95 percent of the
cases. IO More distressing to the DHS is the fact that the test is falsely
negative (that is , infants with NTD who test as normal) in 22 percent of the
cases. II
With unaffected pregnancies testing falsely positive, the level of
maternal anxiety for those women participating has increased dramatically. This has already led participating physicians to conclude that
the "California Alpha-Fetoprotein Screening Program should be halted or
abolished altogether".!2 This verifies the warning by U.S. Surgeon General
C. Everett Koop who, prior to the implementation of the program,
warned: "A positive alpha-fetoprotein test can lead women to have
abortions because they can have the impression that they are carrying a
spina bifida child" .13 James N. Macri Ph.D. , director of the NTD
Laboratory at the State University of New York at Stony Brook, noted
that not all false-positive results can be eliminated so that there is a risk of
aborting a normal fetus. 14 Furthermore, Leroy Walter Ph. D., of the
Kennedy Institute's Center for Bioethics at Georgetown University, said
that some women whose first MSAFP screening test results were positive
were sufficiently frightened "that they went off and secured an abortion
then and there ."1 5 This creates a dilemma for all public health sc reening
programs. A proponent of this program, Prof. Joe Leigh ~ imp so n, head of
the section of human genetics at Northwestern University, even worries
that "unnecessary abortions are likely to occur ... potentially leading to a
loss of public confidence in genetic screening".'"
Since elevated MSAFP levels will lead to 6,263 amniocenteses per year
in California (see Table I) , "the demand for chromosomal st udies of
amniotic fluid fibroblasts [will] be greatly increased becau se, for legal
reasons , it [will] be hazardous to perform amniocentesis without
performing genetic studies".I!>
Analysis of the data in Table I reveals that 323 developing humans will
be identified as having an NTD. The alleged goal of the screening program
is to detect affected infants so that appropriate life-savi ng surgical
intervention can be delivered immediately upon birth. It is appropriate to
determine the number of these affected infants who would require this
intervention .
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Referring to Section I of this report, almost one-half of those infants
with NTDs will have a condition compatible with life: that is , 142 will have
spina bifida cystica. According to Mitchell S. Golbus M . D., professor of
obstetrics, gynecology and pediatrics at the University of California at San
Francisco, the only malformation requiring immediate post-natal sterile
surgical correction is uncovered meningomyelocele. 17 Eighty percent of all
spina bifida cystica births consist of uncovered meningomyeloceles, and 25
percent of these will be stillborn. 18 Thus, only 85 infants would have been
live-born with an uncovered meningomyelocele . Can the cost of screening
justify identifying these infants, especially since effective post-natal
therapy antedates the implementation of the screening program?

Omphalocele
As mentioned, omphalocele can also be detected by an elevated
MSAFP. This condition is rare: its incidence is only I :6000. 19 According to
Dr. Golbus, only a ruptured omphalocele requires immediate post-natal
sterile surgical correction;20 approximately 18.5 percent are ruptured. 21
The sensitivity of the screening program is 73 percent. 22 Of the 35 affected
infants detected by the California Alpha-Fetoprotein Screening Program,
only six will have what Dr. Golbus defines as a surgical emergency- a
ruptured omphalocele. This condition is almost always amenable to
medical and surgical treatment after birth , leaving affected infants with no
physical or mental disability. Late complications have been virtually
nonexistent. 23

Down's Syndrome
The overall incidence of Down's Syndrome is I :800 live births. 24 A low
M SAFP suggests its presence; however , the sensitivity of the test is only 20
percent 25 , and the test is falsely positive in over 97 perce pt of the women
tested. 26 False positive screening tests are obtained with even greater
frequency than is the case in neural tube defect screening . Analysis of the
data in Ta ble II indica tes that 92 women will be determined to be carrying
infants with Down's syndrome by the California Alpha-Fetoprotein
Screening Program. There is no current surgical imperative to identify
these infants antenatally other than for the purpose of abortion.
V.

Data Analysis

The stated goal of the California Alpha-Fetoprotein Screening Program
is to enhance the survival chances of affected infants. Proponents argue
that this can only be done by detecting affected infants antenatally in order
to have a surgical team present at the instant of delivery. immediately
repairing the neural tube defect or ruptured omphalocele. The following
analyses show that the purported goal of the program is not substantiated.
80
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Cost Analysis
The cost of the techniqal aspects of the NTD screening program itself, as
determined from Table I, is :
A.
B.
C.
D.
G.
H.
I.
Total:

$5,550,000
274,725
1,571 ,427
5, 166,975
444,000
2,095 ,236
6,043,950
$21,151 ,313

The costs of the technical aspects of the program for a different level of
utilization (or for other areas in the United States where such a program
might be proposed) can be estimated by:
cost($) = (57.16)x ,
where x = the number of women screened.
This does not include program costs . For example, it is estimated that
one genetic counselor is required for every 150 individuals identified at
risk . 27 Referring to Tables I and II , (Levels D and I, respectively) , it can be
seen that the California program would require up to 91 full-time genetic
counselors. The program will have to rent facilities at each of the 19
regional centers throughout the state. In addition , it will have to fund the
necessary support staff. A proposed program budget is outlined in Table
III.
The total program cost (excluding $743,850 for abortions) of the
proposed screening program would therefore be $28 ,228,566. For
different levels of utilization , the program costs can be estimated by:
Program cost($) = 2778545 + (67.686)x,

,

where x = the number of women screened.
Assuming the unlikely event of full participation, it will cost an average
of $76.29 for each woman screened. Claiming to be self-supporting, the
California Alpha-Fetoprotein Screening Program proposes to charge $40
for every woman who participates. This $36.29 per woman discrepancy
($13.4 M) will have to be compensated by the state of California, Medi-Cal
(Medicaid), and third party insurance carriers. Underutilization of the
program will increase the differential, and it is therefore not surprising that
the Screening Program has already petitioned the legislature for
operational funding. The FY 86 / 87 Budget Act originally authorized
$7M , but this was augmented to $12M as the program was initiated.
Medi-Cal is authorized to pay for the fee for participating women covered
under California's Medicaid program. 28
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Cost:Benefit Analysis

The stated goal of the program is "to detect those infants who would
require immediate surgery". The California Alpha-Fetoprotein Screening
Program will detect 91 developing humans with an uncovered
meningomyelocele or ruptured omphalocele at a total cost of
$28 ,228,566 - that is, $310,204 for each case identified. Since it has been
estimated that the lifetime medical cost of care for each person with spina
bifida is $80,000 29 , it is obvious that the program is not justifiable on a cost:
benefit analysis.
Benefit:Risk Analysis

The human cost of this proposed program is extremely objectionable.
For every 10 developing humans identified with spina bifida cystica,
omphalocele or Down's syndrome, 18 who are affected will be missed and
18 normal unafFecled ones will he killed. (268 affected ones; 469 normal
developing humans killed - see Tables I and II). This analysis does not
even address the enormous public health consequences for the 783 women
undergoing late mid-trimester abortions (see below) JO Obviously , the
program is not designed to enhance the well-being of affected infants;
rather, it is a program of eugenics which institutionalizes discrimination
against handicapped children.
VI.

Goal Analysis

What is the real purpose of identifying these developing humans?
Doctor Berkowitz of the Mount Sinai Medical Center in New York says
that such a program exists so that "a diagnosis can be made prior to the
time when pregnancy can legally be terminated (sic)". 31 The Hastings
Center concludes that the screening program "does detect a serious
condition ... but the condition cannot be arrested or treated except by
aborting the affected fetus." 32 Even the California Department of Health
Services concurs when it states: "As the screening program is implemented
it is estimated that the number of cases diagnosed at birt ~ should drop by
up to 80%. "33 Dr. George Cunningham, Chief of the Genetic Disease
Branch in the California Department of Health Services, states that he
expects 90 percent of women with abnormal screening to obtain
abortions 34 even though their children's disabilities would not usually be
severe.
There is no in ulero treatment for the affected ones. The California
Department of Health Services, in speaking of "prevention strategies", is
using a euphemism to cover the destruction of these developing humans in
Ulero. The program is not even an efficient popUlation purification
program: it must be distressing to the eugenicists in the DHS that this
Screening Program will actually miss 472 affected infants. Since the cost of
discovery for each case (including aneuploidy) is at least $108,106 and
since there is no in Ulero treatment, should not these funds be used to care
for the affected infants rather than to destroy them?
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VII. Ethical Implications
The California Alpha-Fetoprotein Screening Program raises ethical
concerns in at least four areas.
Participation by Mandate
The regulations make it mandatory for physicians to participate in this
"search and destroy" program which is part of the "prevention strategy" of
the Department of Health Services. It is unethical to mandate screening
tests for conditions which are not treatable. It is a violation of conscience
for many physicians to participate in this program.
Participation by Coercion
If an expectant mother decides not to participate, she must sign this
waiver: "No. I refuse to have the alpha-fetoprotein blood screening test
done . I understand and accept the consequences of this decision ." If she
agrees to participate, she signs: "Yes. I request that blood be drawn for the
alpha-fetoprotein screening test."3S The bias is obvious, and its intent is to
frighten the expectant mother into participation.

Discrimination
As discussed in the preceding section, the California Alpha-Fetoprotein
Screening Program institutionalizes discrimination against handicapped
children.
Restriction of Utilization
The Department of Health Services has implemented regulations that
restrict MSAFP testing to the California Alpha-Fetoprotein Screening
Program, at a cost of $40 to every woman participating. The test could be
performed in the private sector for approximately $7. Expectant mothers,
the majority of whom are opposed to it, are thus being coerced to support a
program which promotes abortion.
'
Conclusion
The California Alpha-Fetoprotein Screening Program must be seen for
what it really is: a eugenic population control program masquerading as an
advocacy program for children with disabilities. More normal unaffected
children will be killed than will be the number of abnormal ones identified
by this program. The morality, motives and tactics of the proponents of
this program need to be fully exposed. It is an ethical as well as a civil rights
violation to force expectant mothers and their physicians to participate in
the California Alpha-Fetoprotein Screening Program.
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TABLE I

NTD Screening Program
L
E
V
E
L

2

# of
women

test

A. 370,000 MSAFP

3

4

5

cost ($) % abnormal # abnormal

@15

5

18,500

B.

18,315

MSAFP

@15

60

10,989

C.

10,989

US-I "

@143

57

6,263

O.

6.263

US-II h
amnio'

@825

5

323

E.

323

O&E

@950

Note:

6

comments

1% loss 2°
maternal
anxiety

10/{: loss 2°
to amnio

plus 35 with
omphalocele

185 developing humans voluntarily aborted at Level A;
63 succumbed at Level 0 solely as complications of the screening
program.

Note:

since false negative rate = 220/(·, 95 with NTO m issed: # missed =
([05+(06) (04) (Ol)] / (l-FNR»- 05 = (323+3) / (0.78) - 323 = 95

a = level I ultrasound at $143 per Grossmont Hospital. La Mesa. CA
b = level II ultrasound with amniocentesis for alpha -fetoprotein at $375
per the Fetal Diagnosis and Treatment Center (FOTC). UCSO
c = an additional $450 for karyotyping per the FOTC. UCSO
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TABLE II

Down's Syndrome Screening Program
L
E
V
E
L

2

# of
women

test

3

4

5

6

cost {$} % abnormal # abnormal

comments

F. 370,000 MSAFP

@15

8

29,600

G. 29,600

MSAFP

@15

50

14,800

H . 14,652

US-I "

@143

50

7,326

I.

7,326

US-II "
amnio'

@825

1.25

J.

92

D&E

@950

Note:

148 developing humans voluntarily aborted at Level G;
73 succumbed at Level I solely as complications of the screening
program.

Note:

since false negative rate = 80% , 373 with Down's missed:
# missed = ( [15+(16) (14) (ll)] / (I-FNR) ) - 15' = (92+1) / (0.20)
- 92 = 373

92

I % fetal loss
2° anxiety

1% loss 2°
to amnio

a = level I ultrasound at $143 per Grossmont Hospital, La Mesa, CA
b = level II ultrasound with amniocentesis for alpha-fetoprotein at $375
per the Fetal Diagnosis and Treatment Center (FDTC), UCSD
c = $450 for karyotyping per the FDTC, UCSD
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TABLE III

Technical/Operational Program Budget

Item

Salaries
Program Director
Deputy Director
Admin. As~jstant
Genetic Coun. (9\)
Cler. Assist. (19)
Secretarial (19)
Data Entry Clerk
Temporary Assist.
Regional Cnt. liaison
Fringe Benefits
Tech Costs (Tables I & II)
Travel

$

59,565
$43,875
22,530
2,936,678
293,825
360,000
31,290
10,000
5,265
1,260,050
21 , 151,313
24,000

Other Direct Costs
Telephone
Postage
Duplicating
Printing
Office supplies
Computer costs
Facility leasing

90,000
30,000
90,000
120,000
33,020
125,000
275,000

Indirect Costs

890,000

TOTAL COSTS

86

Total

$28,228,566
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